The study objective was to define the special features of the clinical course of knee joint osteoarthrosis depending on 6-sulfatoxymelatonin urinaryexcretion profile. Materials and methods. We surveyed 141 patients with radiological Stage II-III osteoarthrosis (OA) of the knee joints (18 female subjects). Diagnosis of OA was established on the basis of ACR criteria (1991) and EULAR (2010) recommendations. We determined the AO clinical indexes (Lequesne, WOMAC, KOOS), HAQ functional index, sleep quality and psychoemotional state indicators. ELISA was used to assess 6-sulfatoxymelatonin urinary excretion profile. Results. It was established that 66% of patients with OA of knee joints had a reduced 6-sulfatoxymelatonin urinary excretion compared to this of practically healthy individuals. AO patients with low 6-SMT urinary excretion profiles had higher incidence of severe insomnia and depressive disorders. Reduction in 6-SMT excretion was associated with a moderate increase in pain syndrome and deterioration of physical functions by Lequesne, WOMAC, KOOS, and HAQ indexes. Conclusion. The reducedmelatonin production in OA patients is a factor of more severe clinical course of the disease due to deterioration of the psycho-emotional state, the development of pain syndrome, and functional disorders. 
Osteoarthrosis (OA) is one of the most common chronic diseases, closely associated with the aging process. According to Framingham Osteoarthritis Study, radiologically confirmed knee OA is diagnosed in 13.8% of adults over 26, in 19.2% of patients over 45 years old, and in 37.4% of individuals over 60 [10] . Age is known as unmodified OA development factor [16] . The mechanisms that precondition the osteoarthrosislike articular cartilage transformation are associated with inhibition of expression of clock-genes and disturbances of circadian rhythms [20] . Aging is accompanied with certain inhibition of melatonin production -a key regulator of circadian rhythms, antioxidant, cytoprotector, and neuromodulator [12, 18] . The deficiency of melatonin is considered a factor in the development of age-associated neurodegenerative diseases, insomnia, and metabolic disorders (obesity, type 2 diabetes) [12] . It has been experimentally proved that melatonin has a chondroprotective potential and may be involved in the OA pathogenesis due to the effect on circadian rhythms of chondrocytes [17] . It is known that OA patients more often present with sleep disturbances, depressive and cognitive impairment than general population subjects [9, 19] . Meanwhile, the issue of melatonin production disturbance and its association with the clinical course of OA requires further study.
Study objective was to characterize the clinical course of osteoarthrosis (OA) of the knee joints, depending on the 6-sulfatexymelatonin urinary excretion profile.
Materials and methods of the study
We surveyed 141 patients with radiological Stage II-III osteoarthrosis (OA) of knee joints (76.6% female) of the average age 58.4 ± 7.91 years with a 10.5 ± 6.50-year history of the disease. 47 (33.3%) patients had a combination of knee and hip joint OA. Diagnosis of OA was established on the basis of ACR 1991 criteria for knee and hip joints [5] and EULAR (2010) recommendations [11] .
The study was in line with the basic bioethical standards of the Helsinki Declaration (1989), the Council of Europe Convention on Human Rights and Biomedicine (1977), the relevant provisions of the WHO, the International Code of Medical Ethics (1983) and the laws of Ukraine.
Special peculiarities of clinical course of osteoarthrosis of knee joints depending on 6-hydroxymelatonin-sulfate urinary excretion profile -2/7
The criteria for randomization of patients in the study were as follows: radiologically confirmed Stage II-III osteoarthrosis (OA) of knee joints; age -30-75; duration of the diseaseat least 1 year; and the consent to participate in the study. The non-inclusion criteria were: the reluctance of a patient to participate; oral administration of glucocorticoids; any intra-articular manipulations (injections of glucocorticoids, hyaluronic acid, etc.) during the last 4 weeks; endoprosthetics of knee or hip joints; difficult and uncompensated states; oncological diseases; pregnancy and lactation; alcohol and drug addiction.
For the purposes of clinical evaluation of gonarthrosis symptoms severity, Lequesnealgo-functional index [15] , WOMAC -Western Ontario and McMaster Universities Osteoarthritis Index [22] , and KOOS -Knee Injury and Osteoarthritis Outcome Score [14] were determined. The disturbances of physical functions were evaluated under the HAQ -Health Assessment Questionnaire [8] . The insomnia was assessed using a questionnaire for assessing night sleep [1] and Epworth (Daytime) Sleepiness Scale [13] . The depressive disorders were determined under the Beck Depression Inventory [6] .
The production of melatonin was evaluated against a 6-sulfatexymelatonin (6-SMT) urinary excretion profile, which is considered a stable indicator, closely correlated with night peak blood hormone levels [21] . The 6-sulfatexymelatonin (6-SMT) concentration was determined using ELISA method and 6-sulfatoxymelatonin ELISA Kit (Buhlmann, Sweden). 6-SMT concentration was measured in two portions of urine collected from 18:00 to 22:00 and from 22:00 to 6:00, reflecting production of melatonin in daytime and at night. The average rate of 6-SMT excretion per 1 mg of creatinine was calculated. To establish reference intervals, 36 practically healthy individuals (72.2% -women) from the control group aged 57.1±9.95 (M ± SD) were surveyed.
The results obtained were statistically processed using computer programs MS Excel, IBM Statistics SPSS 22, and STATISTICA 6.0. The reliability of the results was assessed by Student's t-test (with parametric data distribution) and Mann-Whitney U-test (with nonparametric data distribution). The normality of distribution was determined using the ShapiroWilk test. The percentile analysis was used to determine the median, percentiles, and a 95% confidence interval (CI). The relationship between the indicators was estimated against Pearson's correlation coefficient. The odds ratio (OR) was determined. Differences by the frequency of signs were determined by Fisher's exact test. The differences were considered statistically significant with p <0.05.
Study results
It was found that practically healthy individuals from the control group had the 6-SMT urinary excretion level ranging from 13.7 to 31 ng/mg creatinine (95% CI) with a median and interquarantine interval of 25.0 ng/mg creatinine [19.4; 28.3] . The OA patients presented with the 6-SMT excretion ranging from 10.6 to 24.3 ng/mg creatinine (95% CI) with median and interquartile interval 16.1 ng/ml [12.7; 20.6] , which was significantly higher than those in the control group (MannWhitney U-test, Z = 5.977, p <0.001). The OA patients were divided into three groups according to the 6-SMT excretion profile: Group 1 (n=48) included persons with a conditionally normal indicator level > 19.4 ng/mg creatinine (over 25-th percentile of the control group), Group 2 (n = 42) -with a marginally-decreased 6-SMT level -13.7-19.4 ng/mg creatinine (from 5-th to 25-th percentile of the control group), and Group 3 (n = 51) -with a low level of 6-SMT -<13.7 ng/mg creatinine (below the 5-th percentile of the control group). Thus, aberrant 6-SMT levels were found in 66% of patients with OA, including 36.2% of those with lower levels, which was 6.46 times higher than in the control group (p <0.001).
The analysis of clinical and demographic pattern showed that the decrease in the 6-SMT excretion level was associated with an increase in the age of patients, perhaps without evident gender differences ( Table 1 ). The average age of patients with aberrant 6-SMT profiles was higher (by 10.3 and 12.6%) than in patients with normal 6-SMT excretion. Groups of OA patients with normal and aberrant 6-SMT excretion did not differ significantly in the mean duration of the disease. However, patients with a low 6-SMT levels (<13.7 ng/mg creatinine) presented with radiological stage III OA (3.4 times) and combined lesion of knee and hip joints (2.5 times) statistically significantly more often than the patients with normal level of 6-SMT excretion.
In OA patients, the reduction in 6-SMT excretion was associated with an increase in the severity of clinical symptoms of gonarthrosis, functional impairment, and a drop in quality of life by Lequesne, WOMAC, KOOS, and HAQ indexes ( Table 2 ). The most significant differences in the above parameters were observed between patients with normal and low levels of 6-SMT excretion, whereas patients with a marginally low 6-SMT excretion had exaggeration of clinical symptoms that was not statistically significant.
For example, OA patients with a 6-SMT excretion level <13.7 ng/mg creatinine had Lequesne and HAQ indexes statistically significantly higher than patients with a 6-SMT excretion > 19.4 ng/mg creatinine (p <0.01) by 17.6% and 18.6%, respectively. Reduction of 6-SMT excretion in OA patients was associated with an increase in the severity of pain syndrome, stiffness and decreased physical activity under WOMAC index. In patients with a level of 6-SMT <13.7 ng/mg creatinine, the pain, stiffness, physical activity and total WOMAC scores were higher by 26.9; 22.4; 29.2 and 26.1%, respectively, than in patients with a level of 6 SMT excretion > 19.4 ng/mg creatinine (p <0.01). Patients with 6-SMT excretion <13.7 ng/mg creatinine had WOMAC pain score 14.6% higher than patients with 6-SMT excretion 13.7-19.4 ng/mg creatinine (p <0.05). The analysis of KOOS index confirmed that OA patients with a low level of 6-SMT excretion had growing pain syndrome, lower functional performance, and deteriorating quality of life. Patients with 6 SMT <13.7 ng/mg creatinine had scores of pain, symptoms, Subjects with high (> 50 points) WOMAC index ( Figure  1 ) and low (<50 points) KOOS index ( Figure 2 ) dominated among patients with low levels of 6-SMT excretion. Among OA patients with 6-SMT level <13.7 ng/mg creatinine, the proportion of subjects with total WOMAC > 50 points was 1.65 and 1.44 times higher than in patients with 6-SMT level >19.4 ng/mg creatinine and 13.7-19.4 ng/mg creatinine, respectively. Among patients with 6-SMT <13.7 ng/mg creatinine, the proportion of subjects with pain and KOOS scores <50 points was lower 1.48 and 1.72 times than those among patients with 6-SMT level > 19.4 ng/mg creatinine. OA patients with aberrant 6-SMT levels had twice as higher chances of the total WOMAC growth (> 50 points) (OR -2.13; 95% CI -1.05-4.30) than the patients with normal 6-SMT levels.
Sleep disturbances and changes in the psycho-emotional state, including depression, are known as causes of the quality of life deterioration in OA patients. According to the questionnaire on the assessment of sleep quality in the general group of OA patients, 34 (24.1%) subjects without insomnia were found (score > 21 points), 26 (18.4%) subjects presented with Among patients with low 6-SMT profile, the proportion of people with insomnia exceeded that among patients with normal and marginally lowered rates 2.27 and 1.47 times, respectively (Table 3) . With a decrease of 6-SMT excretion <13.7 ng/mg creatinine, OA patients had much higher chances of nocturnal insomnia (OR -7.8; 95% CI -3.01-18.6) and daytime drowsiness (OR -2.68; 95% CI -1.18-6.10) compared to patients with a level of 6-SMT > 19.4 ng/mg creatinine. Moreover, OA patients with a low 6-SMT excretion, had higher incidence of depressive disorders (OR -2.57; 95% CI -1.02-6.46) than those with normal 6-SMT excretion profile.
Reduced production of melatonin in OA patients was accompanied with deepening the clinical symptoms, worsening the quality of life, and depressive changes in the psychoemotional state. Correlation analysis confirmed that 6-SMT excretion in OA patients was strongly associated with the total WOMAC index (r = -0.28; p <0.01), Epworth scale (r = -0.25; p <0.01), but a more close association was observed with sleep disturbances (r = 0.36; p <0.001). It's worthy to note that the group of patients with marginally low 6-SMT excretion statistically significantly differed from the groups with normal and low 6-SMT levels only under Epworth's sleep and daytime sleep profiles, while differences in clinical symptoms of gonarthrosis (under Lequesne, WOMAC, and KOOS indices) were found only in the event of a significant deficiency of melatonin in OA patients.
Discussion
The data we received on inhibition of melatonin production in OA patients and association of low 6-SMT excretion with sleep disorders and psycho-emotional disorders are consistent with the results of other studies. We observed a decrease in the level of urinary melatonin in female patients with primary OA and clinical depression [2] . In the MrOS Sleep Study, the reduction in 6-SMT excretion was closely associated with elevated daytime sleepiness, decreased effectiveness, and reduced sleep time in elderly male subjects [7] . Hypomelatoninemia was associated with increased depression, emotional lability, aggressiveness, and neuroticism in women with the endometrium pathology [4] . A nocturnal decrease in the blood melatonin in patients with fibromyalgia was associated with more pronounced night sleep disorders [3] . According to our research, the deficiency of melatonin was also associated with an increase in the severity of clinical symptoms, decreased functional performance, and deterioration in the quality of life of knee joint OA patients.
Prospects for further research in the subject field
Mechanisms, through which the negative influence of melatonin deficiency on the clinical course of OA may carry into effect, need further study. The study of association of melatonin production disturbance with markers of destruction and remodeling of articular tissues in OA patients is a promising field for further research.
Conclusions
1. 66% of patients with OA of knee joints manifested aberrant levels of 6-SMT urinary excretion, including 36.2% of subjects with low indexes (<13.7 ng/mg creatinine). Poorer 6-SMT excretion was associated with more pronounced insomnia, Epworth's daily drowsiness, and Beck Depression Inventory depression (OR -7.8; 2.68; 2.57).
2. OA patients with a 6-SMT low-excretion (<13.7 ng/mg creatinine) presented with an increase in clinical severity of the disease, deterioration of physical functions, and a decrease in the quality of life by Lequesne, WOMAC, KOOS, and HAQ indexes compared to patients with normal 6-SMT excretion. We established a statistically reliable inverse relationship between the 6-SMT level and the total WOMAC index (r = -0.28). OA patients with aberrant 6-SMT levels had twice as high (OR -2.13) chances of an increase in total WOMAC > 50 points compared to patients with normal 6-SMT excretion.
